NeuroMetrix Names Strategic Growth Executive, Susan M. Bell, RN, BN, as Senior Vice President of Population Health & Value Based Care
NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has
appointed Susan M. Bell as Senior Vice President, Population Health
& Value Based Care. Ms. Bell will be responsible for growing
the Company's DPNCheck® business with a primary focus on the
Medicare Advantage population, and more broadly, expanding the
Company's footprint in the value-based healthcare market. DPNCheck
is a widely used point-of-care test that provides physicians with
fast, accurate and cost-effective screening, diagnosis and
monitoring of peripheral neuropathies. It is often used to stage
the severity of Diabetic Peripheral Neuropathy (DPN), which is the
most common specific cause of peripheral nerve disease and a
ubiquitous long-term complication of diabetes that may lead to foot
ulcers and amputation.
Ms. Bell brings to the company over 20 years of sales, business
development and strategy experience in the Medicare Advantage
sector, and more generally in population health. Ms. Bell was most
recently at eHealth, Inc., where she was Senior Director, Value
Based Provider Partnerships. In this role, she was responsible for
building partnerships with the largest and most innovative Medicare
Advantage plans and at-risk provider networks. Prior to that role,
Ms. Bell was Chief Growth Officer at Cecelia Health where she was
responsible for building the company's chronic disease management
business. Ms. Bell has also held senior roles at CareCentrix, Inc.,
ZeOmega, Inc., Bosch Healthcare, and VITAS Healthcare. She holds a
Bachelor's degree in Nursing from the University of Manitoba and is
licensed as a registered nurse.
"Sue's background in population health, and Medicare Advantage
in particular, is ideally suited to our DPNCheck business. The
technology already has initial adoption by some of the largest
Medicare Advantage plans and we believe there is a substantial
opportunity to grow and expand the business," said Shai N. Gozani
M.D., Ph.D., NeuroMetrix President and Chief Executive Officer. "We
are excited to have someone with Sue's deep experience and energy
join at this time, particularly as we are gearing up to launch our
second generation DPNCheck device. I look forward to working with
Sue to build on our success to date and to take the DPNCheck
business to new heights."
DPNCheck is an automated, fast, accurate, and quantitative nerve
conduction test used to evaluate peripheral neuropathies. It is
designed to be used by clinicians at the point-of-care to
objectively detect, stage, and monitor peripheral neuropathies.
Please visit at www.dpncheck.com.
NeuroMetrix is an innovation-driven company focused on the
development and global commercialization of non-invasive medical
devices for the diagnosis and treatment of pain and neurological
disorders. The Company has three commercial products.
DPNCheck® is a diagnostic device that provides rapid,
point-of-care detection of peripheral neuropathies.
ADVANCE® is a diagnostic device that provides automated,
in-office nerve conduction studies for the evaluation of entrapment
neuropathies. Quell® is a wearable neurostimulation device
indicated for treatment of lower extremity chronic pain. For more
information, visit NeuroMetrix.com.
Source: NeuroMetrix, Inc.Thomas T. HigginsSVP and Chief
Historical Stock Chart
From Dec 2021 to Jan 2022
Historical Stock Chart
From Jan 2021 to Jan 2022